Safety aspects of topical anti-HIV microbicides

Drug Delivery and Development of Anti-HIV Microbicides

Volumn , Issue , 2014, Pages 117-149

  Fichorova, Raina N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974589238     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814463577     Document Type: Chapter

References (115)

1. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Available from URL: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (last accessed Dec 30, 2013).
2. Reardon, S. HIV vaccine raised infection risk. Oct 17, 2013. Available from URL: http://www.nature.com/news/hiv-vaccine-raised-infection-risk-1.13971 (last accessed Dec 30, 2013).
3. Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., Frahm, N., Hural, J., Anude, C., Graham, B. S., Enama, M. E., Adams, E., DeJesus, E., Novak, R. M., Frank, I., Bentley, C., Ramirez, S., Fu, R., Koup, R. A., Mascola, J. R., Nabel, G. J., Montefiori, D. C., Kublin, J., McElrath, M. J., Corey, L., and Gilbert, P. B. (2013). Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine, New Engl. J. Med., 369, 2083-2092.
4. Mugo, N. R., Heffron, R., Donnell, D., Wald, A., Were, E. O., Rees, H., Celum, C., Kiarie, J. N., Cohen, C. R., Kayintekore, K., and Baeten, J. M. (2011). Increased risk of HIV-1 transmission in pregnancy: A prospective study among African HIV-1-serodiscordant couples, AIDS, 25, 1887-1895.
5. Morrison, C., Fichorova, R., Mauck, C., Chen, P-L., Kwok, C., Chipato, T., Salata, R., and Doncel, G. (2012). Biomarkers of cervical inflammation and immunity associated with hormonal contraception, pregnancy and HIV-1 seroconversion, 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA.
6. McGowan, I., Elliott, J., Cortina, G., Tanner, K., Siboliban, C., Adler, A., Cho, D., Boscardin, W. J., Soto-Torres, L., and Anton, P. A. (2007). Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056), J. Acquir. Immune Defic. Syndr., 46, 417-425.
7. Roberts, L., Liebenberg, L., Barnabas, S., and Passmore, J.-A. (2012). Vaginal microbicides to prevent human immunodeficiency virus infection in women: Perspectives on the female genital tract, sexual maturity and mucosal inflammation, Best Pract. Res. Clin. Obstet. Gynaecol., 26, 441-449.
8. Pellett Madan, R., and Herold, B. C. (2013). HIV, sexual violence and special populations: Adolescence and pregnancy, Am. J. Reprod. Immunol., 69 Suppl 1, 61-67.
9. Lard-Whiteford, S. L., Matecka, D., O'Rear, J. J., Yuen, I. S., Litterst, C., and Reichelderfer, P. (2004). Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: An update, J. Acquir. Immune Defic. Syndr., 36, 541-552.
10. Shattock, R. J., and Moore, J. P. (2003). Inhibiting sexual transmission of HIV-1 infection, Nat. Rev. Microbiol., 1, 25-34.
11. Hladik, F., and Doncel, G. F. (2010). Preventing mucosal HIV transmission with topical microbicides: Challenges and opportunities, Antiviral Res., 88 Suppl 1, S3-S9.
12. Mauck, C. K., Baker, J. M., Birnkrant, D. B., Rowe, P. J., and Gabelnick, H. L. (2000). The use of colposcopy in assessing vaginal irritation in research, AIDS, 14, 2221-2227.
13. Mauck, C. K., Weiner, D. H., Lai, J. J., and Schwartz, J. L. (2012). Colposcopy: Still useful in microbicide safety trials?, Sex. Transm. Dis., 39, 465-469.
14. das Neves, J., Rocha, C. M., Gonçalves, M. P., Carrier, R. L., Amiji, M., Bahia, M. F., and Sarmento, B. (2012). Interactions of microbicide nanoparticles with a simulated vaginal fluid, Mol. Pharm., 9, 3347-3356.
15. Shapira-Nahor, O., Kalinkovich, A., Weisman, Z., Greenberg, Z., Nahmias, J., Shapiro, M., Panet, A., and Bentwich, Z. (1998). Increased susceptibility to HIV-1 infection of peripheral blood mononuclear cells from chronically immune-activated individuals, AIDS, 12, 1731-1733.
16. Alfano, M., and Poli, G. (2002). The cytokine network in HIV infection, Curr. Mol. Med., 2, 677-689.
17. Kreiss, J., Ngugi, E., Holmes, K., Anzala, A., Holton, D., and Plummer, F. (1992). Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes, JAMA, 268, 477-482.
18. Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiegne-Traore, V., Uaheowitchai, C., Karim, S., Masse, B., Perriens, J., and Laga, M. (2002). Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial, Lancet, 360, 971-977.
19. Marais, D., Carrara, H., Kay, P., Ramjee, G., Allan, B., and Williamson, A.-L. (2006). The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers, Virus Res., 121, 220-222.
20. Hillier, S. L., Moench, T., Shattock, R., Black, R., Reichelderfer, P., and Veronese, F. (2005). In vitro and in vivo: The story of nonoxynol 9, J. Acquir. Immune Defic. Syndr., 39, 1-8.
21. Fichorova, R. N., Tucker, L. D., and Anderson, D. J. (2001). The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission, J. Infect. Dis., 184, 418-428.
22. Fichorova, R. N., Rheinwald, J. G., and Anderson, D. J. (1997). Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins, Biol. Reprod., 57, 847-855.
23. Fichorova, R. N., and Anderson, D. J. (1999). Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells, Biol. Reprod., 60, 508-514.
24. Canny, G. O., Trifonova, R. T., Kindelberger, D. W., Colgan, S. P., and Fichorova, R. N. (2006). Expression and function of bactericidal/permeability-increasing protein in human genital tract epithelial cells, J. Infect. Dis., 194, 498-502.
25. Fichorova, R. N., Trifonova, R. T., Gilbert, R. O., Costello, C. E., Hayes, G. R., Lucas, J. J., and Singh, B. N. (2006). Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells, Infect. Immun., 74, 5773-5779.
26. Singh, B. N., Hayes, G. R., Lucas, J. J., Sommer, U., Viseux, N., Mirgorodskaya, E., Trifonova, R. T., Sassi, R. R., Costello, C. E., and Fichorova, R. N. (2009). Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function, Glycoconj. J., 26, 3-17.
27. Fichorova, R. N., Lee, Y., Yamamoto, H. S., Takagi, Y., Hayes, G. R., Goodman, R. P., Chepa-Lotrea, X., Buck, O. R., Murray, R., Kula, T., Beach, D. H., Singh, B. N., and Nibert, M. L. (2012). Endobiont viruses sensed by the human host: beyond conventional antiparasitic therapy, PloS One, 7, e48418.
28. Jin, F. Y., Nathan, C., Radzioch, D., and Ding, A. (1997). Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide, Cell, 88, 417-426.
29. Fichorova, R. N., Yamamoto, H. S., Delaney, M. L., Onderdonk, A. B., and Doncel, G. F. (2011). Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action, MBio, 2, e00168-11.
30. Yamamoto, H. S., Xu, Q., and Fichorova, R. N. (2013). Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide, BMC Microbiol., 13, 4.
31. Draper, D. L., Landers, D. V., Krohn, M. A., Hillier, S. L., Wiesenfeld, H. C., and Heine, R. P. (2000). Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections, Am. J. Obstet. Gynecol., 183, 1243-1248.
32. Valore, E. V., Wiley, D. J., and Ganz, T. (2006). Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis, Infect. Immun., 74, 5693-5702.
33. Novak, R. M., Donoval, B. A., Graham, P. J., Boksa, L. A., Spear, G., Hershow, R. C., Chen, H. Y., and Landay, A. (2007). Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection, Clin. Vaccine Immunol., 14, 1102-1107.
34. Huppert, J. S., Huang, B., Chen, C., Dawood, H. Y., and Fichorova, R. N. (2013). Clinical evidence for the role of Trichomonas vaginalis in regulation of the secretory leukocyte protease inhibitor in the female genital tract, J. Infect. Dis., 207, 1462-1470.
35. McNeely, T. B., Dealy, M., Dripps, D. J., Orenstein, J. M., Eisenberg, S. P., and Wahl, S. M. (1995). Secretory leukocyte protease inhibitor:A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro, J. Clin. Invest., 96, 456-464.
36. Wahl, S. M., McNeely, T. B., Janoff, E. N., Shugars, D., Worley, P., Tucker, C., and Orenstein, J. M. (1997). Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1, Oral Dis., 3 Suppl 1, S64-S69.
37. Wahl, S. M., Worley, P., Jin, W., McNeely, T. B., Eisenberg, S., Fasching, C., Orenstein, J. M., and Janoff, E. N. (1997). Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues, Am. J. Pathol., 150, 1275-1284.
38. Shugars, D. C., and Wahl, S. M. (1998). The role of the oral environment in HIV-1 transmission, J. Am. Dent. Assoc., 129, 851-858.
39. Semba, R. D., Kumwenda, N., Taha, T. E., Hoover, D. R., Quinn, T. C., Lan, Y., Mtimavalye, L., Broadhead, R., Miotti, P. G., van der Hoeven, L., and Chiphangwi, J. D. (1999). Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women, J. Hum. Lact., 15, 301-306.
40. Farquhar, C., VanCott, T. C., Mbori-Ngacha, D. A., Horani, L., Bosire, R. K., Kreiss, J. K., Richardson, B. A., and John-Stewart, G. C. (2002). Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk, J. Infect. Dis., 186, 1173-1176.
41. Moutsopoulos, N. M., Greenwell-Wild, T., and Wahl, S. M. (2006). Differential mucosal susceptibility in HIV-1 transmission and infection, Adv. Dent. Res., 19, 52-56.
42. McNeely, T. B., Shugars, D. C., Rosendahl, M., Tucker, C., Eisenberg, S. P., and Wahl, S. M. (1997). Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription, Blood, 90, 1141-1149.
43. Taborda, N. A., Catano, J. C., Delgado, J. C., Rugeles, M. T., and Montoya, C. J. (2012). Higher SLPI expression, lower immune activation, and increased frequency of immune cells in a cohort of Colombian HIV-1 controllers, J. Acquir. Immune Defic. Syndr., 60, 12-19.
44. Milligan, G. N., Dudley, K. L., Bourne, N., Reece, A., and Stanberry, L. R. (2002). Entry of inflammatory cells into the mouse vagina following application of candidate microbicides: Comparison of detergent-based and sulfated polymer-based agents, Sex. Transm. Dis., 29, 597-605.
45. Fichorova, R. N., Bajpai, M., Chandra, N., Hsiu, J. G., Spangler, M., Ratnam, V., and Doncel, G. F. (2004). Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives, Biol. Reprod., 71, 761-769.
46. Catalone, B. J., Miller, S. R., Ferguson, M. L., Malamud, D., Kish-Catalone, T., Thakkar, N. J., Krebs, F. C., Howett, M. K., and Wigdahl, B. (2005). Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G, Biomed. Pharmacother., 59, 430-437.
47. Fichorova, R. N., Zhou, F., Ratnam, V., Atanassova, V., Jiang, S., Strick, N., and Neurath, A. R. (2005). Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation, Antimicrob. Agents Chemother., 49, 323-335.
48. Ayehunie, S., Cannon, C., Lamore, S., Kubilus, J., Anderson, D. J., Pudney, J., and Klausner, M. (2006). Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products, Toxicol. in vitro, 20, 689-698.
49. Cone, R. A., Hoen, T., Wong, X., Abusuwwa, R., Anderson, D. J., and Moench, T. R. (2006). Vaginal microbicides: Detecting toxicities in vivo that paradoxically increase pathogen transmission, BMC Infect. Dis., 6, 90.
50. Fletcher, P. S., Wallace, G. S., Mesquita, P. M., and Shattock, R. J. (2006). Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants, Retrovirology, 3, 46.
51. Trifonova, R. T., Pasicznyk, J. M., and Fichorova, R. N. (2006). Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo, Antimicrob. Agents Chemother., 50, 4005-4010.
52. Cummins, J. E., Jr., Guarner, J., Flowers, L., Guenthner, P. C., Bartlett, J., Morken, T., Grohskopf, L. A., Paxton, L., and Dezzutti, C. S. (2007). Preclinical testing of candidate topical microbicides for anti-HIV-1 activity and tissue toxicity in a human cervical explant culture, Antimicrob. Agents Chemother., 51, 1770-1779.
53. D'Cruz, O. J., and Uckun, F. M. (2007). Preclinical evaluation of a dualacting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat, Toxicol. Pathol., 35, 910-927.
54. Galen, B. T., Martin, A. P., Hazrati, E., Garin, A., Guzman, E., Wilson, S. S., Porter, D. D., Lira, S. A., Keller, M. J., and Herold, B. C. (2007). A comprehensive murine model to evaluate topical vaginal microbicides: Mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety, J. Infect. Dis., 195, 1332-1339.
55. Gali, Y., Ariën, K. K., Praet, M., Van den Bergh, R., Temmerman, M., Delezay, O., and Vanham, G. (2010). Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity, J. Virol. Methods, 165, 186-197.
56. Gali, Y., Delezay, O., Brouwers, J., Addad, N., Augustijns, P., Bourlet, T., Hamzeh-Cognasse, H., Ariën, K. K., Pozzetto, B., and Vanham, G. (2010). In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides, Antimicrob. Agents Chemother., 54, 5105-5114.
57. Yang, J., Li, L., Jin, H., Tan, S., Qiu, J., Yang, L., Ding, Y., Jiang, Z. H., Jiang, S., and Liu, S. (2012). Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission, AIDS Res. Hum. Retroviruses, 28, 1498-1508.
58. Zhong, M., He, B., Yang, J., Bao, R., Zhang, Y., Zhou, D., Chen, Y., Li, L., Han, C., Yang, Y., Sun, Y., Cao, Y., Li, Y., Shi, W., Jiang, S., Zhang, X., and Yan, H. (2012). L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide, Antimicrob. Agents Chemother., 56, 3121-3132.
59. das Neves, J., Araújo, F., Andrade, F., Michiels, J., Ariën, K. K., Vanham, G., Amiji, M., Bahia, M. F., and Sarmento, B. (2013). In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine, Mol. Pharm., 10, 2793-2807.
60. McGowan, I., Hoesley, C., Cranston, R. D., Andrew, P., Janocko, L., Dai, J. Y., Carballo-Dieguez, A., Ayudhya, R. K., Piper, J., Hladik, F., and Mayer, K. (2013). A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007), PLoS One, 8, e60147.
61. Fichorova, R. N. (2004). Guiding the vaginal microbicide trials with biomarkers of inflammation, J. Acquir. Immune Defic. Syndr., 37 Suppl 3, S184-S193.
62. Obiero, J., Mwethera, P. G., and Wiysonge, C. S. (2012). Topical microbicides for prevention of sexually transmitted infections, Cochrane Database Syst. Rev., 6, CD007961.
63. Keller, M. J., Guzman, E., Hazrati, E., Kasowitz, A., Cheshenko, N., Wallenstein, S., Cole, A. L., Cole, A. M., Profy, A. T., Wira, C. R., Hogarty, K., and Herold, B. C. (2007). PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity, AIDS, 21, 467-476.
64. Anderson, D. J., Williams, D. L., Ballagh, S. A., Barnhart, K., Creinin, M. D., Newman, D. R., Bowman, F. P., Politch, J. A., Duerr, A. C., and Jamieson, D. J. (2009). Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: Effects on markers of inflammation and innate immunity in cervicovaginal fluid, Am. J. Reprod. Immunol., 61, 21-129.
65. Mauck, C. K., Lai, J. J., Weiner, D. H., Chandra, N., Fichorova, R. N., Dezzutti, C. S., Hillier, S. L., Archer, D. F., Creinin, M. D., Schwartz, J. L., Callahan, M. M., and Doncel, G. F. (2013). Toward early safety alert endpoints:Exploring biomarkers suggestive of microbicide failure, AIDS Res. Hum. Retroviruses, 29, 1475-1486.
66. Bollen, L. J., Blanchard, K., Kilmarx, P. H., Chaikummao, S., Connolly, C., Wasinrapee, P., Srivirojana, N., Achalapong, J., Tappero, J. W., and McNicholl, J. M. (2008). No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial, J. Acquir. Immune Defic. Syndr., 47, 253-257.
67. Trifonova, R. T., Doncel, G. F., and Fichorova, R. N. (2009). Polyanionic microbicides modify toll-like receptor-mediated cervicovaginal immune responses, Antimicrob. Agents Chemother., 53, 1490-1500.
68. Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., and Taylor, D. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, Science, 329, 1168-1174.
69. van der Straten, A., Van Damme, L., Haberer, J. E., and Bangsberg, D. R. (2012). Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention, AIDS, 26, F13-F19.
70. Lacey, C. J., Woodhall, S., Qi, Z., Sawant, S., Cowen, M., McCormack, S., and Jiang, S. (2010). Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial, Int. J. STD AIDS, 21, 714-717.
71. Leyva, F. J., Bakshi, R. P., Fuchs, E. J., Li, L., Caffo, B. S., Goldsmith, A. J., Ventuneac, A., Carballo-Diéguez, A., Du, Y., Leal, J. P., Lee, L. A., Torbenson, M. S., and Hendrix, C. W. (2013). Isoosmolar enemas demonstrate preferential gastrointestinal distribution, safety, and acceptability compared with hyperosmolar and hypoosmolar enemas as a potential delivery vehicle for rectal microbicides, AIDS Res. Hum. Retroviruses, 29, 1487-1495.
72. Naranbhai, V., Abdool Karim, S. S., Altfeld, M., Samsunder, N., Durgiah, R., Sibeko, S., Abdool Karim, Q., and Carr, W. H. (2012). Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel, J. Infect. Dis., 206, 993-1001.
73. Roberts, L., Passmore, J. A., Williamson, C., Little, F., Naranbhai, V., Sibeko, S., Walzl, G., Abdool Karim, Q., and Abdool Karim, S. (2011). Genital tract inflammation in women participating in the CAPRISA TFV microbicide trial who became infected with HIV: A mechanism for breakthrough infection?, 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA.
74. Witkin, S. S., Linhares, I. M., and Giraldo, P. (2007). Bacterial flora of the female genital tract: Function and immune regulation, Best Pract. Res. Clin. Obstet. Gynaecol., 21, 347-354.
75. Cherpes, T. L., Marrazzo, J. M., Cosentino, L. A., Meyn, L. A., Murray, P. J., and Hillier, S. L. (2008). Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis, Sex. Transm. Infect., 84, 57-61.
76. Gajer, P., Brotman, R. M., Bai, G., Sakamoto, J., Schutte, U. M., Zhong, X., Koenig, S. S., Fu, L., Ma, Z. S., Zhou, X., Abdo, Z., Forney, L. J., and Ravel, J. (2012). Temporal dynamics of the human vaginal microbiota, Sci. Transl. Med., 4, 132ra152.
77. Onderdonk, A. B., Lee, M. L., Lieberman, E., Delaney, M. L., and Tuomala, R. E. (2003). Quantitative microbiologic models for preterm delivery, J. Clin. Microbiol., 41, 1073-1079.
78. Verhelst, R., Verstraelen, H., Claeys, G., Verschraegen, G., Van Simaey, L., De Ganck, C., De Backer, E., Temmerman, M., and Vaneechoutte, M. (2005). Comparison between gram stain and culture for the characterization of vaginal microflora: Definition of a distinct grade that resembles grade I microflora and revised categorization of grade I microflora, BMC Microbiol., 5, 61.
79. Spear, G. T., Sikaroodi, M., Zariffard, M. R., Landay, A. L., French, A. L., and Gillevet, P. M. (2008). Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis, J. Infect. Dis., 198, 1131-1140.
80. Verhelst, R., Verstraelen, H., Claeys, G., Verschraegen, G., Delanghe, J., Van Simaey, L., De Ganck, C., Temmerman, M., and Vaneechoutte, M. (2004). Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis, BMC Microbiol., 4, 16.
81. Othman, M., Neilson, J. P., and Alfirevic, Z. (2007). Probiotics for preventing preterm labour, Cochrane Database Syst. Rev., (1), CD005941.
82. Neish, A. S., Gewirtz, A. T., Zeng, H., Young, A. N., Hobert, M. E., Karmali, V., Rao, A. S., and Madara, J. L. (2000). Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination, Science, 289, 1560-1563.
83. Zeuthen, L. H., Fink, L. N., and Frokiaer, H. (2008). Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-beta, Immunology, 123, 197-208.
84. Donato, K. A., Gareau, M. G., Wang, Y. J. J., and Sherman, P. M. (2010). Lactobacillus rhamnosus GG attenuates interferon-gamma and tumor necrosis factor-alpha-induced barrier dysfunction and proinflammatory signalling, Microbiology, 156 Pt 11, 3288-3297.
85. Libby, E. K., Pascal, K. E., Mordechai, E., Adelson, M. E., and Trama, J. P. (2008). Atopobium vaginae triggers an innate immune response in an in vitro model of bacterial vaginosis, Microbes Infect., 10, 439-446.
86. Fashemi, B., Delaney, M. L., Onderdonk, A. B., and Fichorova, R. N. (2013). Effects of feminine hygiene products on the vaginal mucosal biome, Microb. Ecol. Health Dis., 24, 19703.
87. Fichorova, R. N., Buck, O. R., Yamamoto, H. S., Fashemi, T., Dawood, H. Y., Fashemi, B., Hayes, G. R., Beach, D. H., Takagi, Y., Delaney, M. L., Nibert, M. L., Singh, B. N., and Onderdonk, A. B. (2013). The villain team-up or how Trichomonas vaginalis and bacterial vaginosis alter innate immunity in concert, Sex. Transm. Infect., 89, 460-466.
88. Hedges, S. R., Barrientes, F., Desmond, R. A., and Schwebke, J. R. (2006). Local and systemic cytokine levels in relation to changes in vaginal flora, J. Infect. Dis., 193, 556-562.
89. Nikolaitchouk, N., Andersch, B., Falsen, E., Strömbeck, L., and Mattsby-Baltzer, I. (2008). The lower genital tract microbiota in relation to cytokine-, SLPI-and endotoxin levels: Application of checkerboard DNA-DNA hybridization (CDH), APMIS, 116, 263-277.
90. McGroarty, J. A., Soboh, F., Bruce, A. W., and Reid, G. (1990). The spermicidal compound nonoxynol-9 increases adhesion of Candida species to human epithelial cells in vitro, Infect. Immun., 58, 2005-2007.
91. Hooton, T. M., Fennell, C. L., Clark, A. M., and Stamm, W. E. (1991). Nonoxynol-9: Differential antibacterial activity and enhancement of bacterial adherence to vaginal epithelial cells, J. Infect. Dis., 164, 1216-1219.
92. Watts, D. H., Rabe, L., Krohn, M. A., Aura, J., and Hillier, S. L. (1999). The effects of three nonoxynol-9 preparations on vaginal flora and epithelium, J. Infect. Dis., 180, 426-437.
93. Schreiber, C. A., Meyn, L. A., Creinin, M. D., Barnhart, K. T., and Hillier, S. L. (2006). Effects of long-term use of nonoxynol-9 on vaginal flora, Obstet. Gynecol., 107, 136-143.
94. Van Damme, L., Govinden, R., Mirembe, F. M., Guédou, F., Solomon, S., Becker, M. L., Pradeep, B. S., Krishnan, A. K., Alary, M., Pande, B., Ramjee, G., Deese, J., Crucitti, T., and Taylor, D. (2008). Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission, New Engl. J. Med., 359, 463-472.
95. Mauck, C., Weiner, D. H., Ballagh, S., Creinin, M., Archer, D. F., Schwartz, J., Pymar, H., Lai, J. J., and Callahan, M. (2001). Single and multiple exposure tolerance study of cellulose sulfate gel: A phase I safety and colposcopy study, Contraception, 64, 383-391.
96. Anderson, R. A., Feathergill, K. A., Diao, X. H., Cooper, M. D., Kirkpatrick, R., Herold, B. C., Doncel, G. F., Chany, C. J., Waller, D. P., Rencher, W. F., and Zaneveld, L. J. (2002). Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent, J. Androl., 23, 426-438.
97. Scordi-Bello, I. A., Mosoian, A., He, C., Chen, Y., Cheng, Y., Jarvis, G. A., Keller, M. J., Hogarty, K., Waller, D. P., Profy, A. T., Herold, B. C., and Klotman, M. E. (2005). Candidate sulfonated and sulfated topical microbicides: Comparison of anti-human immunodeficiency virus activities and mechanisms of action, Antimicrob. Agents Chemother., 49, 3607-3615.
98. El-Sadr, W. M., Mayer, K. H., Maslankowski, L., Hoesley, C., Justman, J., Gai, F., Mauck, C., Absalon, J., Morrow, K., Masse, B., Soto-Torres, L., and Kwiecien, A. (2006). Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women, AIDS, 20, 1109-1116.
99. Schwartz, J. L., Mauck, C., Lai, J. J., Creinin, M. D., Brache, V., Ballagh, S. A., Weiner, D. H., Hillier, S. L., Fichorova, R. N., and Callahan, M. (2006). Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: A randomized double-blind phase I safety study, Contraception, 74, 133-140.
100. Doh, A. S., Ngoh, N., Roddy, R., Lai, J. J., Linton, K., and Mauck, C. (2007). Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days, Contraception, 76, 245-249.
101. Verstraelen, H., Verhelst, R., Claeys, G., De Backer, E., Temmerman, M., and Vaneechoutte, M. (2009). Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora, BMC Microbiol., 9, 116.
102. Simões, J. A., Citron, D. M., Aroutcheva, A., Anderson, R. A., Jr., Chany, C. J., 2nd, Waller, D. P., Faro, S., and Zaneveld, L. J. (2002). Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis, Antimicrob. Agents Chemother., 46, 2692-2695.
103. Ravel, J., Gajer, P., Fu, L., Mauck, C. K., Koenig, S. S., Sakamoto, J., Motsinger-Reif, A. A., Doncel, G. F., and Zeichner, S. L. (2012). Twicedaily application of HIV microbicides alter the vaginal microbiota, MBio, 3, e00370-12.
104. Fichorova, R. N., Lai, J. J., Schwartz, J. L., Weiner, D. H., Mauck, C. K., and Callahan, M. M. (2011). Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials, Cytokine, 55, 134-140.
105. Li, L., Ben, Y., Zhu, Z., Li, W., Xu, J., and Zhang, X. (2012). Minocycline down-regulates topical mucosal inflammation during the application of microbicide candidates, PLoS One, 7, e43211.
106. Krebs, F. C., Miller, S. R., Catalone, B. J., Fichorova, R., Anderson, D., Malamud, D., Howett, M. K., and Wigdahl, B. (2002). Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate, Antimicrob. Agents Chemother., 46, 2292-2298.
107. Doncel, G. F., Chandra, N., and Fichorova, R. N. (2004). Preclinical assessment of the proinflammatory potential of microbicide candidates, J. Acquir. Immune Defic. Syndr., 37 Suppl 3, S174-S180.
108. Kleine-Lowinski, K., Rheinwald, J. G., Fichorova, R. N., Anderson, D. J., Basile, J., Munger, K., Daly, C. M., Rosl, F., and Rollins, B. J. (2003). Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells, Int. J. Cancer, 107, 407-415.
109. Shen, Z., Fahey, J. V., Bodwell, J. E., Rodriguez-Garcia, M., Rossoll, R. M., Crist, S. G., Patel, M. V., and Wira, C. R. (2013). Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts, PLoS One, 8, e69854.
110. Richardson-Harman, N., Lackman-Smith, C., Fletcher, P. S., Anton, P. A., Bremer, J. W., Dezzutti, C. S., Elliott, J., Grivel, J. C., Guenthner, P., Gupta, P., Jones, M., Lurain, N. S., Margolis, L. B., Mohan, S., Ratner, D., Reichelderfer, P., Roberts, P., Shattock, R. J., and Cummins, J. E., Jr. (2009). Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis, J. Clin. Microbiol., 47, 530-3539.
111. Hjelm, B. E., Berta, A. N., Nickerson, C. A., Arntzen, C. J., and Herbst-Kralovetz, M. M. (2010). Development and characterization of a three-dimensional organotypic human vaginal epithelial cell model, Biol. Reprod., 82, 617-627.
112. Center for Drug Evaluation and Research (1995). Guidance for industry. Guidance for development of vaginal contraceptive drugs. Available from URL: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM131211.pdf (last accessed Dec 31, 2013).
113. Trifonova, R. T., Bajpai, M., Pasicznyk, J. M., Chandra, N., Doncel, G. F., and Fichorova, R. N. (2007). Biomarkers of leukocyte traffic and activation in the vaginal mucosa, Biomarkers, 12, 608-622.
114. Stumpf, R. M., Wilson, B. A., Rivera, A., Yildirim, S., Yeoman, C. J., Polk, J. D., White, B. A., and Leigh, S. R. (2013). The primate vaginal microbiome: Comparative context and implications for human health and disease, Am. J. Phys. Anthropol., 152 Suppl 57, 119-134.
115. Cohen, C. R., Moscicki, A. B., Scott, M. E., Ma, Y., Shiboski, S., Bukusi, E., Daud, I., Rebbapragada, A., Brown, J., and Kaul, R. (2010). Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa, AIDS, 24, 2069-2074.